Sites throughout the U.S. and Canada are seeking patients with newly diagnosed or relapsed anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. This clinical trial is designed to determine whether a new non-steroidal treatment, when added to standard of care treatment can improve the remission rate, kidney function, and/or improve vasculitis symptoms. All…...
RITAZAREM Trial – Now Enrolling Patients
The RITAZAREM Trial is an international, open label, randomized controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis. Rituximab is now established as an effective drug for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis following major European and US trials reported in 2010. After a time, its effect…...
Mepolizumab Trial for EGPA/CSS Patients Now Enrolling
The purpose of this randomized, double-blind study is to investigate the efficacy and safety of mepolizumab (300 milligram mg administered subcutaneously every four weeks) compared with a placebo over a 52-week study treatment period in subjects with relapsing or refractory Eosinophilic granulomatosis with polyangiitis (EGPA/Churg Strauss syndrome) receiving standard of…...
PROMIS – Quality of Life Survey
Vivek Nagaraja, MD and Dinesh Khanna, MD, MSc at the University of Michigan Health System, are conducting a piece of research called PROMIS (Patient Reported Outcomes Measurement Information System) in rheumatology. The research involves an online survey catered to patients with various rheumatologic conditions. Interested patients are highly encouraged to…...
VCRC Genetic Repository One-Time DNA Study
The Vasculitis Clinical Research Consortium is pleased to let you know the University of Michigan, Ann Arbor is now enrolling patients for our study: VCRC Genetic Repository One-Time DNA Study About this study ~ The purpose of this study is to identify genes that increase the risk of developing vasculitis.…...
